妊娠期他汀使用与先天畸形风险的挪威全国研究
BACKGROUND AND AIMS: Statins and other lipid-modifying agents (LMAs) have traditionally been contraindicated during pregnancy due to concerns about harmful fetal effects; however, the risks associated with exposure to statins and other LMAs in human pregnancies remain unclear.…
要点
- 他汀暴露与停药者相比,任何、重大、轻微畸形均无关联。
- 更新荟萃分析未提示重大畸形(OR 1.06)或心脏畸形(OR 1.24)风险增加。
核心结论
- 全国性研究和更新荟萃分析未观察到妊娠早期他汀或其他调脂药暴露与先天畸形之间存在显著关联。
- 尽管把握度有限可能漏检弱关联,但 findings 不支持他汀暴露与先天畸形存在强或独立关联。
研究设计与样本
- 采用通用逆方差法和随机效应模型进行荟萃分析,更新2022年荟萃分析。
临床怎么用
- 本研究结果不支持妊娠早期他汀暴露与先天畸形存在强或独立关联,可为临床风险评估提供参考。
- 但研究把握度有限,不能排除弱但临床相关的关联,决策仍需个体化。
局限性
- 研究把握度有限,可能未能检测到弱但临床相关的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Statins and other lipid-modifying agents (LMAs) have traditionally been contraindicated during pregnancy due to concerns about harmful fetal effects; however, the risks associated with exposure to statins and other LMAs in human pregnancies remain unclear. Therefore, this study aimed to examine the associations between statin and LMA exposure in pregnancy and congenital malformations in offspring, while updating a 2022 meta-analysis with the results from the present study. METHODS: National registry data were linked for all pregnant women in Norway in 2005-18. Associations between first-trimester statin prescription fills and congenital malformations were estimated with mixed-effects logistic regression, adjusting for age, parity, pre-pregnancy folate use, smoking in early pregnancy, comorbidity, and co-medication. Meta-analyses were performed with the generic inverse-variance method and random-effects model. RESULTS: Congenital malformations occurred among 34 755 out of 803 830 (4.3%) statin non-exposed pregnancies, 74 out of 1255 (5.9%) statin-discontinuer pregnancies, and 19 out of 283 (6.7%) statin-exposed pregnancies. Adjusted odds ratios (ORs) for exposed vs non-exposed pregnancies were 1.30 [95% confidence interval (CI) .81-2.09] for any, 1.15 (.61-2.19) for major, and 1.47 (.75-2.89) for minor malformations. In analyses of exposed vs discontinuer pregnancies, there were no associations between statin exposure and any (adjusted OR 1.01, 95% CI .59-1.72), major (1.08, .52-2.25), or minor malformations (.94, .44-2.00). Results were similar across sensitivity analyses. There was also no association between any LMA exposure and heart malformations (adjusted OR 1.22, 95% CI .50-3.01). The updated meta-analysis suggested no increased risk of major (adjusted OR 1.06, 95% CI .86-1.31) or heart malformations (1.24, 95% CI .94-1.64). CONCLUSIONS: In this large, nationwide study and updated meta-analysis, no significant association was observed between first-trimester exposure to statins or other LMAs and congenital malformations. Although limited power may have prevented detection of weak but clinically relevant associations, the findings do not support a strong or independent association between statin exposure in pregnancy and congenital malformations.
引用
- Christensen JJ, Holven KB, Bogsrud MP, et al. Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study. Eur Heart J. 2026. PMID: 40838827. doi:10.1093/eurheartj/ehaf592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。